Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1894401 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9022847 | 0.92 | LTB4R (0.84) | LTB4RLTB4R2 | |
| SCHEMBL9023332 | 0.91 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL9022467 | 0.89 | LTB4R (0.80) | LTB4RLTB4R2 | |
| SCHEMBL9023608 | 0.84 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9023836 | 0.84 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL14021681 | 0.83 | LTB4R (0.88) | LTB4RLTB4R2 | |
| SCHEMBL14021678 | 0.83 | LTB4R (0.81) | LTB4RLTB4R2 | |
| SCHEMBL9023335 | 0.82 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL1894403 | 0.82 | LTB4R (0.69) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250236594-A1 | MODIFIED AMINO ACIDS | SUTRO BIOPHARMA, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-12269801-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250090676-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | SUTRO BIOPHARMA, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-12071477-B2 | Anti-folate receptor alpha antibody conjugated with hemiasterlins | SUTRO BIOPHARMA, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4114852-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC GLUTAMINE TAGS, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | Sutro Biopharma, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11548852-B2 | Modified amino acids | SUTRO BIOPHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220362394-A1 | ANTI-BCMA ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4074728-A1 | MODIFIED PEPTIDES COMPRISING AN AZIDO GROUP | Sutro Biopharma, Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| CN-114796520-A | anti-CD 74 antibody conjugates, compositions comprising anti-CD 74 antibody conjugates, and methods of use of anti-CD 74 antibody conjugates | 苏特罗生物制药公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11344626-B2 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-109069664-B | anti-CD 74 antibody conjugates, compositions comprising anti-CD 74 antibody conjugates, and methods of use of anti-CD 74 antibody conjugates | 苏特罗生物制药公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3962951-A1 | ANTI-BCMA ANTIBODY CONJUGATES | Sutro Biopharma, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3584255-B1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA INC (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071477-B2 | Anti-folate receptor alpha antibody conjugated with hemiasterlins | FOLR2, FOLR1, FCGRT | LTB4R 374/4885LTB4R2 568/4885 |
| US-11548852-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | LTB4R 2470/4885LTB4R2 3135/4885 |
| US-12252552-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | FCGR2A, FCGR3B, FCGR1A | LTB4R 2559/4885LTB4R2 2999/4885 |
| US-20250090676-A1 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USES | FOLR1, FOLR2, DHFR | LTB4R 1331/4885LTB4R2 2515/4885 |
| US-20250304723-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | FCGR2A, FCGR3B, FCGR1A | LTB4R 2559/4885LTB4R2 2999/4885 |
| US-20240026008-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | LTB4R 3875/4885LTB4R2 4034/4885 |
| US-12269801-B2 | Modified amino acids | PTMS, DNPEP, ANPEP | LTB4R 2470/4885LTB4R2 3135/4885 |
| US-20240182580-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | LTB4R 3875/4885LTB4R2 4034/4885 |
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | LTB4R 1090/4885LTB4R2 2055/4885 |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | CD74, CD63, CD99 | LTB4R 3602/4885LTB4R2 3801/4885 |
| US-20250236594-A1 | MODIFIED AMINO ACIDS | PTMS, DNPEP, ANPEP | LTB4R 2470/4885LTB4R2 3135/4885 |
| US-20250236674-A9 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD63, CD99 | LTB4R 3875/4885LTB4R2 4034/4885 |
| US-11344626-B2 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | DNPEP, VSIG8, LNPEP | LTB4R 4294/4885LTB4R2 4475/4885 |
| US-20220362394-A1 | ANTI-BCMA ANTIBODY CONJUGATES | BCR, CD79B, BCDIN3D | LTB4R 3920/4885LTB4R2 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.